Health Economics Research Unit, University of Aberdeen, Aberdeen, UK.
Colorectal Dis. 2010 Jun;12(6):587-93. doi: 10.1111/j.1463-1318.2009.01889.x.
Haemorrhoidal disease is a common condition causing considerable distress to individuals and significant cost to healthcare services. This paper explored the cost-effectiveness of stapled haemorrhoidopexy (SH) compared with the non-surgical intervention, rubber band ligation (RBL), for grade II symptomatic circumferential haemorrhoids.
An economic evaluation alongside a randomized controlled trial conducted between October 2002 and February 2005. Adults were recruited and randomized to either SH or RBL. The same surgeon performed all procedures and investigators were blinded until analyses were completed. Primary outcomes measured at 52 weeks were cumulative costs to the NHS, clinical diagnosis of recurrence and quality adjusted life years (QALYs).
Sixty symptomatic men and women with confirmed clinical diagnosis of grade II symptomatic haemorrhoids were randomized. Loss to follow-up was up to 10% at 52 weeks. The mean cost for SH was greater than RBL (mean difference: 1483 pounds, 95% CI: 1339-1676); disease recurrence was lower (OR = 0.18, 95% CI: 0.03-0.86); and there was no evidence of a statistically significant difference in QALYs (-0.014, 95% CI: -0.076 to 0.051). SH was associated with a modest incremental cost per recurrence avoided at 12 months follow-up (4945 pounds). Based on current data, it was considered highly unlikely to be cost-effective in terms of incremental cost per QALY.
There is insufficient evidence about the cost-effectiveness of SH for grade II haemorrhoids to recommend its routine use in place of RBL. Further information is needed from larger trials with a longer-term follow-up to inform subsequent economic evaluation.
痔病是一种常见病症,会给患者带来极大的痛苦,并给医疗保健服务带来巨大的成本。本文探讨了吻合器痔固定术(SH)与非手术干预(橡皮圈结扎术,RBL)治疗 II 度环状内痔的成本效益。
这是一项在 2002 年 10 月至 2005 年 2 月进行的随机对照试验的同时进行的经济评估。招募成年患者并随机分为 SH 组或 RBL 组。所有手术均由同一位外科医生进行,在分析完成之前,调查人员处于盲态。52 周时主要的终点是 NHS 的累积成本、临床复发诊断和质量调整生命年(QALYs)。
60 例有明确 II 度内痔临床诊断的症状性男女患者被随机分组。52 周时的失访率高达 10%。SH 的平均费用高于 RBL(平均差异:1483 英镑,95%CI:1339-1676);疾病复发率较低(OR=0.18,95%CI:0.03-0.86);且 QALYs 没有统计学意义上的差异(-0.014,95%CI:-0.076 至 0.051)。在 12 个月随访时,每避免一次复发,SH 的增量成本为 4945 英镑。根据目前的数据,从增量成本效益比的角度来看,SH 治疗 II 度痔的性价比并不高。
目前尚无足够证据支持 SH 治疗 II 度痔的成本效益,因此不推荐其常规用于替代 RBL。需要更大规模、随访时间更长的试验来提供更多信息,以进一步进行经济评估。